{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:11:57Z","timestamp":1768889517580,"version":"3.49.0"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"Importance<\/jats:title>With the ongoing relaxation of guidelines to prevent COVID-19 transmission, particularly in hospital settings, medically vulnerable groups, such as patients with cancer, may experience a disparate burden of COVID-19 mortality compared with the general population.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate COVID-19 mortality among US patients with cancer compared with the general US population during different waves of the pandemic.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used data from the Center for Disease Control and Prevention\u2019s Wide-Ranging Online Data for Epidemiologic Research database to examine COVID-19 mortality among US patients with cancer and the general population from March 1, 2020, to May 31, 2022. The number of deaths due to COVID-19 during the 2021 to 2022 winter Omicron surge was compared with deaths during the preceding year\u2019s COVID-19 winter surge (when the wild-type SARS-CoV-2 variant was predominant) using mortality ratios. Data were analyzed from July 21 through August 31, 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Pandemic wave during which the wild-type variant (December 2020 to February 2021), Delta variant (July 2021 to November 2021), or Omicron variant (December 2021 to February 2022) was predominant.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Number of COVID-19 deaths per month.<\/jats:p><\/jats:sec>Results<\/jats:title>The sample included 34 350 patients with cancer (14 498 females [42.2%] and 19 852 males [57.8%]) and 628 156 members of the general public (276 878 females [44.1%] and 351 278 males [55.9%]) who died from COVID-19 when the wild-type (December 2020-February 2021), Delta (July 2021-November 2021), and winter Omicron (December 2021-February 2022) variants were predominant. Among patients with cancer, the greatest number of COVID-19 deaths per month occurred during the winter Omicron period (n\u2009=\u20095958): at the peak of the winter Omicron period, there were 18% more deaths compared with the peak of the wild-type period. In contrast, among the general public, the greatest number of COVID-19 deaths per month occurred during the wild-type period (n\u2009=\u2009105\u202f327), and at the peak of the winter Omicron period, there were 21% fewer COVID-19 deaths compared with the peak of the wild-type period. In subgroup analyses by cancer site, COVID-19 mortality increased the most, by 38%, among patients with lymphoma during the winter Omicron period vs the wild-type period.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings of this cross-sectional study suggest that patients with cancer had a disparate burden of COVID-19 mortality during the winter Omicron wave compared with the general US population. With the emergence of new, immune-evasive SARS-CoV-2 variants, many of which are anticipated to be resistant to monoclonal antibody treatments, strategies to prevent COVID-19 transmission should remain a high priority.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.3066","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T15:55:42Z","timestamp":1693497342000},"page":"1417","source":"Crossref","is-referenced-by-count":19,"title":["Deaths Due to COVID-19 in Patients With Cancer During Different Waves of the Pandemic in the US"],"prefix":"10.1001","volume":"9","author":[{"given":"Alexandra L.","family":"Potter","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedha","family":"Vaddaraju","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaek","family":"Venkateswaran","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arian","family":"Mansur","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simar S.","family":"Bajaj","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew V.","family":"Kiang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupam B.","family":"Jena","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"National Bureau of Economic Research, Cambridge, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Fu Jeffrey","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital, Boston"},{"name":"Mongan Institute Health Policy Research Center, Massachusetts General Hospital, Boston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"coi230041r2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021.","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"issue":"27","key":"coi230041r3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19\u2014COVID-NET, 10 states, March 2020-February 2022.","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"coi230041r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6815","article-title":"Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer.","volume":"9","author":"Gong","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi230041r5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(21)00475-8","article-title":"Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.","volume":"22","author":"Twohig","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"coi230041r6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1001\/jama.2022.9609","article-title":"Association of Omicron vs wild-type SARS-CoV-2 variants with hospital-onset SARS-CoV-2 infections in a US regional hospital system.","volume":"328","author":"Klompas","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"coi230041r7","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1038\/s41467-022-33328-3","article-title":"Household transmission of the SARS-CoV-2 Omicron variant in Denmark.","volume":"13","author":"Lyngse","year":"2022","journal-title":"Nat Commun"},{"key":"coi230041r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070695","article-title":"Risk of COVID-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.","volume":"378","author":"Ward","year":"2022","journal-title":"BMJ"},{"issue":"10323","key":"coi230041r9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"coi230041r10","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California.","volume":"28","author":"Lewnard","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"coi230041r12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15585\/mmwr.mm7106a4","article-title":"Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants\u2014United States, June 2021\u2013January 2022.","volume":"71","author":"Lambrou","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"coi230041r13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.15585\/mmwr.mm7023a3","article-title":"Genomic surveillance for SARS-CoV-2 variants circulating in the United States, December 2020-May 2021.","volume":"70","author":"Paul","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"coi230041r15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis.","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"issue":"26","key":"coi230041r16","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.22.00088","article-title":"Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-hodgkin lymphoma and chronic lymphocytic leukemia.","volume":"40","author":"Chang","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi230041r1","unstructured":"Quinn K. Op-Ed: Now that the CDC has dropped masking, a plea to doctors and hospitals. Los Angeles Times; September 27, 2022. Accessed October 30, 2022 https:\/\/www.msn.com\/en-us\/health\/medical\/op-ed-now-that-the-cdc-has-dropped-masking-a-plea-to-doctors-and-hospitals\/ar-AA12jDZ0"},{"key":"coi230041r11","unstructured":"Centers for Disease Control and Prevention. Provisional multiple cause of death by single race, 2018-present. Accessed July 21, 2022. https:\/\/wonder.cdc.gov\/mcd-icd10-provisional.html"},{"key":"coi230041r14","unstructured":"USAFacts. US coronavirus vaccine tracker. Accessed April 20, 2023. https:\/\/usafacts.org\/visualizations\/covid-vaccine-tracker-states\/"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2809037\/jamaoncology_potter_2023_oi_230041_1697125873.87235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T15:08:00Z","timestamp":1697728080000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2809037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.3066","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}